PapersFlow Research Brief
Gallbladder and Bile Duct Disorders
Research Guide
What is Gallbladder and Bile Duct Disorders?
Gallbladder and bile duct disorders are a group of pathological conditions affecting the gallbladder and biliary tract, including cholelithiasis, choledocholithiasis, cholangitis, biliary strictures, and malignancies such as cholangiocarcinoma and gallbladder cancer.
The field encompasses over 102,312 published works focused on surgical, endoscopic, and pharmacological management of these disorders. Key contributions include standardized classifications of surgical complications and definitions for postoperative issues like pancreatic fistula and posthepatectomy liver failure. Endoscopic interventions such as sphincterotomy carry defined complication rates influenced by procedural indications and techniques.
Research Sub-Topics
Biliary Tract Cancer Chemotherapy
This sub-topic evaluates gemcitabine-cisplatin regimens and novel agents for advanced cholangiocarcinoma and gallbladder cancer. Researchers conduct phase III trials and biomarker analyses.
Postoperative Pancreatic Fistula Grading
This sub-topic refines ISGPF definitions and severity grading for clinically relevant pancreatic fistulas after pancreaticobiliary surgery. Researchers validate updates across international cohorts.
Endoscopic Sphincterotomy Complications
This sub-topic classifies and manages risks like bleeding, perforation, and pancreatitis from biliary sphincterotomy. Researchers develop consensus guidelines and prevention strategies.
Posthepatectomy Liver Failure
This sub-topic defines and grades liver dysfunction after hepatectomy for gallbladder/bile duct tumors using ISGLS criteria. Researchers assess volumetrics and regenerative factors.
Classification of Surgical Complications Biliary
This sub-topic applies Clavien-Dindo schemes to cholecystectomy and bile duct surgery outcomes. Researchers audit morbidity in large registries.
Why It Matters
Gallbladder and bile duct disorders impact clinical practice through standardized tools for assessing surgical outcomes and managing complications. "Classification of Surgical Complications" by Dindo et al. (2004) provides a reliable system used worldwide for quality assessment in surgery, cited 29,749 times. In advanced biliary tract cancer, "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" by Valle et al. (2010) demonstrated a significant survival advantage with cisplatin plus gemcitabine over gemcitabine alone, establishing it as a standard treatment option with 4,258 citations. Recent approvals like zanidatamab for HER2-positive biliary tract cancer address unmet needs in targeted therapy, while zenocutuzumab shows clinical benefit in rare bile duct cancers.
Reading Guide
Where to Start
"Classification of Surgical Complications" by Dindo et al. (2004) is the ideal starting paper as it provides the foundational, highly cited (29,749 times) framework for understanding and reporting complications across all gallbladder and bile duct surgeries.
Key Papers Explained
"Classification of Surgical Complications" by Dindo et al. (2004) establishes the core system for complication grading, which underpins subsequent works like "Postoperative pancreatic fistula: An international study group (ISGPF) definition" by Bassi et al. (2005) and its 2016 update by Bassi et al., applying standardized grading to pancreaticobiliary fistulas. "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" by Valle et al. (2010) builds on complication management by demonstrating survival benefits in advanced disease. "Complications of Endoscopic Biliary Sphincterotomy" by Freeman et al. (1996) and "Endoscopic sphincterotomy complications and their management" by Cotton et al. (1991) connect through risk factor analysis for endoscopic procedures.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints focus on algorithmic management of common bile duct stones and mechanisms of biliary strictures with novel therapies. News highlights zenocutuzumab clinical benefits in rare bile duct cancers and zanidatamab approval for HER2-positive biliary tract cancer. Open cholangiocarcinoma trials and cell line atlases for bile duct cancers indicate active recruitment and modeling efforts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Classification of Surgical Complications | 2004 | Annals of Surgery | 29.7K | ✓ |
| 2 | Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Trac... | 2010 | New England Journal of... | 4.3K | ✓ |
| 3 | Postoperative pancreatic fistula: An international study group... | 2005 | Surgery | 4.2K | ✕ |
| 4 | The 2016 update of the International Study Group (ISGPS) defin... | 2016 | Surgery | 3.9K | ✕ |
| 5 | Endoscopic sphincterotomy complications and their management: ... | 1991 | Gastrointestinal Endos... | 2.8K | ✕ |
| 6 | Complications of Endoscopic Biliary Sphincterotomy | 1996 | New England Journal of... | 2.5K | ✓ |
| 7 | A lexicon for endoscopic adverse events: report of an ASGE wor... | 2010 | Gastrointestinal Endos... | 2.3K | ✕ |
| 8 | International consensus guidelines 2012 for the management of ... | 2012 | Pancreatology | 2.3K | ✕ |
| 9 | Posthepatectomy liver failure: A definition and grading by the... | 2011 | Surgery | 2.2K | ✕ |
| 10 | Practice Guidelines in Acute Pancreatitis | 2006 | The American Journal o... | 2.1K | ✕ |
In the News
Zenocutuzumab Shows Clinical Benefit in Rare Bile Duct ...
* AACR Blog: Cancer Research Catalyst * Cancer Today Magazine # Zenocutuzumab Shows Clinical Benefit in Rare Bile Duct Cancer October 22, 2025
Zanidatamab Is a Breakthrough in HER2- Positive Biliary ...
The accelerated approval of zanidatamab marks a significant advancement in the treatment of patients with HER2+ BTC. As the first HER2-targeted bispecific antibody approved for this indication in t...
Progress in Liver and Bile Duct Cancer: New Insights from ...
* Rare Cancers * Anal Cancer * Appendiceal Cancer * Gallbladder Cancer * Small Intestine Cancer * Hereditary Cancers * Resources * Education
Scientists build cell line atlas of deadly cancers of the bile ...
Funding
Current Cholangiocarcinoma Trials
# Current Cholangiocarcinoma Trials Listed here are the clinical trials for those with cholangiocarcinoma (bile duct cancer) or gall bladder cancer, currently open and recruiting in the UK.
Code & Tools
## Repository files navigation ## TAGNet: A transformer-based axial guided network for bile duct segmentation
## Repository files navigation # CDS-Library: Clinical Decision Support File Library
ACR Assist is a clinical decision support framework designed to provide structured clinical guidance to radiologists in a manner that allows this c...
{{ message }} ## Pinned 1. duct ductPublic Server-side application framework for Clojure Clojure 1.1k 51 2. core corePublic The co...
This python library aims at: 1. Facilitating the manipulation of healthcare data of various modalities (e.g., structured, text, audio data) for the...
Recent Preprints
Bile Duct Diseases
The primary NIH organization for research onBile Duct Diseasesis the National Institute of Diabetes and Digestive and Kidney Diseases ## Other Languages Find health information in languages other ...
Management of common bile duct stones: a comprehensive review
high-quality comparative effectiveness research. This review synthesizes current evidence to advocate for a personalized, algorithmic approach to CBD stones management, balancing procedural risks, ...
Frontiers | Mechanisms of biliary stricture and novel therapeutic strategies
progression and leads to biliary stricture. Similarly, hepatic arterial ischemia can suppress the function of hepatocellular bile transporters, aggravating cholestasis and further damaging the stru...
Choledocholithiasis and Cholangitis
## General references 1. 1. Stinton LM, Shaffer EA . Epidemiology of gallbladder disease: Cholelithiasis and cancer.*Gut Liver.*2012;6(2):172-187, 2012. doi: 10.5009/gnl.2012.6.2.172
Cholelithiasis
8. 8\. He L, Wang J, Ping F, et al . Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized C...
Latest Developments
Recent research indicates significant advances in understanding biliary tract cancers, including the identification of new subtypes and potential therapeutic targets, as well as efforts to optimize treatment strategies for gallbladder and bile duct disorders (Broad Institute, 2025; Nature Reviews Gastroenterology & Hepatology, 2025).
Sources
Frequently Asked Questions
What is the standard chemotherapy for advanced biliary tract cancer?
"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer" by Valle et al. (2010) showed that cisplatin plus gemcitabine provides a significant survival advantage over gemcitabine alone in patients with advanced biliary tract cancer. This regimen is associated with manageable toxicity and is recommended as an appropriate treatment option.
How are surgical complications classified in gallbladder and bile duct surgery?
"Classification of Surgical Complications" by Dindo et al. (2004) introduced a reliable classification system applicable worldwide for quality assessment in surgery. It standardizes reporting of complications across procedures involving the gallbladder and bile ducts.
What factors influence complications of endoscopic biliary sphincterotomy?
"Complications of Endoscopic Biliary Sphincterotomy" by Freeman et al. (1996) established that complication rates vary primarily with the indication for the procedure and endoscopic technique, rather than patient age or general medical condition. This guides risk stratification in bile duct interventions.
What defines postoperative pancreatic fistula in biliary surgery?
"Postoperative pancreatic fistula: An international study group (ISGPF) definition" by Bassi et al. (2005) provides a standardized definition for postoperative pancreatic fistula occurring in pancreaticobiliary surgeries. The 2016 update by Bassi et al. refines grading for improved clinical applicability.
What recent treatments are available for bile duct cancer?
Zanidatamab received accelerated approval as the first HER2-targeted bispecific antibody for HER2-positive biliary tract cancer in the US. Zenocutuzumab demonstrates clinical benefit in rare bile duct cancers as reported in recent news coverage.
Open Research Questions
- ? How can procedural risks and stone characteristics be optimally balanced in personalized management of common bile duct stones?
- ? What novel therapeutic strategies can interrupt the vicious cycle of injury, stasis, and fibrosis in biliary strictures?
- ? Which patient subgroups derive the greatest survival benefit from cisplatin-gemcitabine combinations in biliary tract cancer?
- ? How do emerging HER2-targeted therapies like zanidatamab compare to chemotherapy standards in HER2-positive biliary cancers?
- ? What imaging and AI models improve early detection of bile duct malignancies?
Recent Trends
Approvals of zanidatamab (April 2025) as the first HER2 bispecific antibody for biliary tract cancer and zenocutuzumab showing benefits in rare bile duct cancers (October 2025) mark targeted therapy advances.
Preprints emphasize personalized algorithms for common bile duct stones (November 2025) and biliary stricture mechanisms (September 2025).
The field maintains 102,312 works with ongoing trials for cholangiocarcinoma.
Research Gallbladder and Bile Duct Disorders with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Gallbladder and Bile Duct Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.